
Quarterly report 2024-Q1
added 05-06-2024
ShockWave Medical Revenue 2011-2026 | SWAV
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue ShockWave Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 730 M | 490 M | 237 M | 67.8 M | 42.9 M | 12.3 M | 1.72 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 730 M | 1.72 M | 226 M |
Quarterly Revenue ShockWave Medical
| 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 219 M | 186 M | 180 M | 161 M | - | 131 M | 121 M | 93.6 M | - | 65.2 M | 55.9 M | 31.9 M | - | 19.6 M | 10.3 M | 15.2 M | - | 11.3 M | 10 M | 7.27 M | - | 3.6 M | 2.28 M | 1.32 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 219 M | 1.32 M | 69.8 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Medical devices industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Apyx Medical Corporation
APYX
|
52.8 M | $ 3.72 | 0.95 % | $ 153 M | ||
|
AxoGen
AXGN
|
225 M | $ 33.03 | -4.08 % | $ 1.52 B | ||
|
Butterfly Network
BFLY
|
82.1 M | $ 4.07 | -1.09 % | $ 862 M | ||
|
AdaptHealth Corp.
AHCO
|
3.24 B | $ 12.25 | 1.79 % | $ 1.66 B | ||
|
GenMark Diagnostics, Inc.
GNMK
|
172 M | - | - | $ 1.77 B | ||
|
Bruker Corporation
BRKR
|
3.37 B | $ 36.66 | -0.27 % | $ 5.46 K | ||
|
Boston Scientific Corporation
BSX
|
20.1 B | $ 62.57 | -0.4 % | $ 92.6 B | ||
|
Apollo Endosurgery
APEN
|
76.9 M | - | - | $ 475 M | ||
|
Acutus Medical
AFIB
|
7.16 M | - | -26.83 % | $ 2.62 M | ||
|
Avinger
AVGR
|
7.65 M | - | -20.74 % | $ 369 K | ||
|
Axonics Modulation Technologies
AXNX
|
274 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
12.3 M | - | 1.37 % | $ 20.5 M | ||
|
Allied Healthcare Products
AHPI
|
6.02 M | - | 3.58 % | $ 2.21 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
1.59 M | - | -5.86 % | $ 30.6 M | ||
|
ClearPoint Neuro
CLPT
|
37 M | $ 9.41 | 0.48 % | $ 266 M | ||
|
CONMED Corporation
CNMD
|
1.37 B | $ 34.54 | -0.72 % | $ 1.07 B | ||
|
Cytosorbents Corporation
CTSO
|
37.1 M | $ 0.62 | 5.64 % | $ 38.6 M | ||
|
BioSig Technologies
BSGM
|
40 K | - | 37.08 % | $ 85.7 M | ||
|
Delcath Systems
DCTH
|
85.2 M | $ 9.76 | 1.35 % | $ 350 M | ||
|
EDAP TMS S.A.
EDAP
|
44.1 M | $ 3.5 | 3.24 % | $ 131 M | ||
|
Cardiovascular Systems
CSII
|
236 M | - | 0.15 % | $ 844 M | ||
|
Edwards Lifesciences Corporation
EW
|
6.07 B | $ 81.26 | 0.26 % | $ 47.5 B | ||
|
Cutera
CUTR
|
49.5 M | - | -10.19 % | $ 1.99 M | ||
|
FONAR Corporation
FONR
|
97.6 M | $ 18.6 | 0.04 % | $ 122 M | ||
|
CryoLife, Inc.
CRY
|
253 M | - | -4.14 % | $ 702 M | ||
|
Dynatronics Corporation
DYNT
|
27.4 M | - | 14.99 % | $ 929 K | ||
|
Align Technology
ALGN
|
4 B | $ 170.52 | -0.05 % | $ 12.8 B | ||
|
Helius Medical Technologies
HSDT
|
644 K | $ 1.87 | 0.27 % | $ 1.14 M | ||
|
Eargo
EAR
|
37.2 M | - | - | $ 10.2 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
1.61 B | $ 9.31 | -2.31 % | $ 717 M | ||
|
Inogen
INGN
|
349 M | $ 6.42 | 3.38 % | $ 171 M | ||
|
IRIDEX Corporation
IRIX
|
52.7 M | $ 0.99 | 1.47 % | $ 16.8 M | ||
|
IRadimed Corporation
IRMD
|
83.8 M | $ 96.6 | 0.38 % | $ 1.23 B | ||
|
Integer Holdings Corporation
ITGR
|
1.85 B | $ 85.01 | -2.12 % | $ 2.95 B | ||
|
Conformis
CFMS
|
62 M | - | - | $ 16.4 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.25 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
41 M | - | 0.03 % | $ 1.58 B | ||
|
OrthoPediatrics Corp.
KIDS
|
236 M | $ 15.95 | -0.68 % | $ 374 M | ||
|
Misonix, Inc.
MSON
|
62.5 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
2.55 M | - | - | $ 111 M | ||
|
Second Sight Medical Products
EYES
|
1 K | - | -0.97 % | $ 54.4 M | ||
|
LENSAR
LNSR
|
58.4 M | $ 5.97 | -1.49 % | $ 71.4 M | ||
|
Pulmonx Corporation
LUNG
|
90.5 M | $ 1.38 | 3.38 % | $ 56.1 M | ||
|
Medtronic PLC
MDT
|
33.5 B | $ 86.52 | -0.13 % | $ 111 B | ||
|
MiMedx Group
MDXG
|
419 M | $ 3.89 | -0.89 % | $ 575 M | ||
|
Intersect ENT, Inc.
XENT
|
80.6 M | - | - | $ 955 M | ||
|
Myomo
MYO
|
40.9 M | $ 0.69 | 3.22 % | $ 28.9 M |